⌘+K

Pulse Explore Communities Researchers Journals

Browser extensionInstagram

Home Communities Explore

August 7, 2024Open Access

FIGURE 4 from Persistent Ethnicity-Associated Disparity in Antitumor Effectiveness of Immune Checkpoint Inhibitors Despite Equal Access

Marcus A. Florez Jan O. Kemnade Nan Chen Wendy Du Anita L. Sabichi Daniel Y. Wang Quillan Huang Courtney N. Miller-Chism Aparna Jotwani Albert C. Chen David J. Hernandez Vlad C. Sandulache

View Full Paper

Ask AI

Bookmark

Share

Ask about this paper

Answers are grounded in this paper and cite their sources.

Ask your own question…

Abstract

Immune-related adverse events (irAE) within the entire treatment cohort. A, Overall irAE rate as a function of race/ethnic group. B, ORR as a function of irAE for the ICI monotherapy cohort. PR, partial response; SD, stable disease; PD, progressive disease.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Florez et al. (2024) studied this question.

synapsesocial.com/papers/68e5d251b6db643587568e03 https://doi.org/10.1158/2767-9764.26517032

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context:

1FIGURE 2 from Persistent Ethnicity-Associated Disparity in Antitumor Effectiveness of Immune Checkpoint Inhibitors Despite Equal Access2024
2FIGURE 3 from Persistent Ethnicity-Associated Disparity in Antitumor Effectiveness of Immune Checkpoint Inhibitors Despite Equal Access2024
3FIGURE 1 from Persistent Ethnicity-Associated Disparity in Antitumor Effectiveness of Immune Checkpoint Inhibitors Despite Equal Access2024
4TABLE 1 from Persistent Ethnicity-Associated Disparity in Antitumor Effectiveness of Immune Checkpoint Inhibitors Despite Equal Access2024
5TABLE 1 from Persistent Ethnicity-Associated Disparity in Antitumor Effectiveness of Immune Checkpoint Inhibitors Despite Equal Access2024
6Abstract 914: Racial disparities in immune-related adverse events with immune checkpoint inhibitors: A systematic review and meta-analysis.Meta-Analysis · 2026
7Disparities in adverse events during cancer immunotherapyClinical Trial · 2026 · 1 citations
8Impact of ethnicity and immune-related adverse events (IRAE) on outcomes for non-small cell lung cancer (NSCLC) patients treated with immune checkpoint inhibitors.Cohort Study · 2022 · 12 citations